Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
Authors
Keywords
Cancer, Sunitinib, Pulsatile, High dose, Alternative scheduling, CAM model, Apoptosis, Autophagy, Tumor growth
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 35, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-09-07
DOI
10.1186/s13046-016-0411-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis
- (2014) Ying-Yun Guan et al. BIOMATERIALS
- A 2weeks on and 1week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma
- (2014) Y.G. Najjar et al. EUROPEAN JOURNAL OF CANCER
- Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer
- (2014) A. Jo Chien et al. JOURNAL OF CLINICAL ONCOLOGY
- Determining the optimal dose in the development of anticancer agents
- (2014) Ron H. J. Mathijssen et al. Nature Reviews Clinical Oncology
- Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example
- (2014) Mauricio Burotto et al. PLoS One
- Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells
- (2013) M Santoni et al. BRITISH JOURNAL OF CANCER
- Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis
- (2013) Guilhem Bousquet et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases—One with a remarkable thoracic response as well
- (2013) J.L. Kuiper et al. LUNG CANCER
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Axitinib for the Management of Metastatic Renal Cell Carcinoma
- (2013) Bernard Escudier et al. Drugs in research & development
- Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
- (2013) Krastan B. Blagoev et al. Cell Reports
- Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
- (2012) N Pécuchet et al. BRITISH JOURNAL OF CANCER
- Tumor Cell Autophagy as an Adaptive Response Mediating Resistance to Treatments Such as Antiangiogenic Therapy
- (2012) Y.-L. Hu et al. CANCER RESEARCH
- Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients
- (2012) A. W. Griffioen et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
- (2012) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
- (2012) King Pan Ng et al. NATURE MEDICINE
- Variability of Sorafenib Toxicity and Exposure over Time: A Pharmacokinetic/Pharmacodynamic Analysis
- (2012) P. Boudou-Rouquette et al. ONCOLOGIST
- FDA Approval Summary: Sunitinib for the Treatment of Progressive Well-Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
- (2012) G. M. Blumenthal et al. ONCOLOGIST
- Determining the optimal dose and schedule of sunitinib
- (2011) Cristina Suarez et al. CANCER
- Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
- (2011) Carlos H. Barrios et al. CANCER
- Antiangiogenic Agent Sunitinib Transiently Increases Tumor Oxygenation and Suppresses Cycling Hypoxia
- (2011) S. Matsumoto et al. CANCER RESEARCH
- Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
- (2011) K. J. Gotink et al. CLINICAL CANCER RESEARCH
- Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene
- (2011) Jing Yang et al. INTERNATIONAL JOURNAL OF CANCER
- Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
- (2011) Jennifer Arrondeau et al. INVESTIGATIONAL NEW DRUGS
- Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry
- (2010) R. Honeywell et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Vascular Endothelial Growth Factor: Much More than an Angiogenesis Factor
- (2010) Donald R. Senger MOLECULAR BIOLOGY OF THE CELL
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species
- (2009) Joshua Ö. Haznedar et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
- (2009) A. Gregory Sorensen et al. CANCER RESEARCH
- A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
- (2009) B. E. Houk et al. CLINICAL CANCER RESEARCH
- Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
- (2009) Annamaria Rapisarda et al. DRUG RESISTANCE UPDATES
- Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders
- (2009) N. Singh et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis
- (2009) Maria Galluzzo et al. JOURNAL OF CLINICAL INVESTIGATION
- Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
- (2009) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis
- (2008) Neil P. Shah et al. CANCER CELL
- Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis
- (2008) Elena I. Deryugina et al. HISTOCHEMISTRY AND CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started